Javascript must be enabled to continue!
Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
View through CrossRef
Abstract
Background
Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of
Mycobacterium tuberculosis
(
MTB
) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of
rpoB
gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results.
Methods
Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample.
Results
A total of 100 specimens were reported as
MTB Detected Rifampicin Resistance Detected
by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations.
Conclusion
Mutations associated with Probe E (codons 529–533) region were identified as the commonest
rpoB
gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum.
Springer Science and Business Media LLC
Title: Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
Description:
Abstract
Background
Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of
Mycobacterium tuberculosis
(
MTB
) and mutations that confer Rifampicin resistance.
Rifampicin resistance is determined based on any mutation in the 81 bp of
rpoB
gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533).
In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results.
Methods
Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively.
All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample.
Results
A total of 100 specimens were reported as
MTB Detected Rifampicin Resistance Detected
by Xpert® MTB/RIF assay.
More than half (55%) of these results were reported from male patients.
The median age was 28.
0 years (5 months to 88 years).
Majorities (62%) of the cases were detected from sputum.
Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38).
The most common mutations (81.
0%) were found in the Probe E region followed by Probe D (10.
0%), and Probe B (3.
0%).
Mutations in Probe A and Probe C regions were not observed.
However, six (6.
0%) Rifampicin resistance cases were found without any missed probe type.
The delta Ct max is ≥4.
3.
No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations.
Conclusion
Mutations associated with Probe E (codons 529–533) region were identified as the commonest
rpoB
gene mutations.
The Rifampicin resistance results found without any identified missing probe needs further study.
The lower DNA amount was observed in extrapulmonary specimens compared with sputum.
Related Results
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Background: Molecular examination using Xpert MTB RIF and Xpert MTB RIF Ultra was introduced by WHO in 2010 as a fast and practical supporting examination in detecting Mycobacteriu...
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Abstract
Background
Uganda introduced Xpert® MTB/RIF assay into its TB diagnostic algorithm in January 2012. In July 2018, this...
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Abstract
Objective: To evaluate Gene Xpert MTB/RIF and Multiplex PCRfor detection of Mycobacterium tuberculosis and Rifampicin resistance comparing with gold standard MGIT 96...
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
Abstract
Introduction: The value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensiti...
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Abstract
Background: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin res...
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Does Xpert MTB/RIF Assay Give Rifampicin Resistance Results Without Identified Mutation? Review of Cases from Addis Ababa, Ethiopia.
Abstract
Background: Xpert MTB/RIF Assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resi...
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Abstract
Background
The main advantage of GeneXpert MTB/RIF® (Xpert) molecular diagnostic technology is the rapid detection of M.tuberculosis DNA and mutations associated with rifa...
DIAGNÓSTICO MOLECULAR DE TUBERCULOSIS Y EVALUACIÓN DEL GEN RPOB UTILIZANDO GENEXPERT MTB/RIF Y GENEXPERT MTB/RIF ULTRA
DIAGNÓSTICO MOLECULAR DE TUBERCULOSIS Y EVALUACIÓN DEL GEN RPOB UTILIZANDO GENEXPERT MTB/RIF Y GENEXPERT MTB/RIF ULTRA
Meta: Identificación y análisis de las mutaciones de sondas del gen rpoB de Mycobacterium tuberculosis asociadas a resistencia a rifampicina utilizando GeneXpert MTB/RIF y GeneXper...

